Article

Combination of Volasertib and Rapamycin Inhibits the Regrowth of TSC2-Deficient Tumors

2022-11-03

Abstract excerpt

<h4>ABSTRACT</h4> Mutations in TSC1 and TSC2 lead to hyperactivation of mTORC1 and cause Tuberous Sclerosis Complex (TSC) and pulmonary Lymphangioleiomyomatosis (LAM). Rapamycin and rapalogs are potent inhibitors of mTORC1 activity and are approved for the treatment of TSC and LAM. Nevertheless, rapalogs do not cause tumor cell death, and cessation of therapy leads to tumor regrowth. Polo-like kinase 1 (PLK1) i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cfdd1acf-757a-58bc-9a7a-7b90eb71a801
DOI: 10.1101/2022.11.02.512640

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combination of Volasertib and Rapamycin Inhibits the Regrowth of TSC2-Deficient TumorsDOI 10.1101/2022.11.02.512640Read

TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.Semantic proximity Read

Mammalian Target of Rapamycin Signaling and Autophagy: Roles in Lymphangioleiomyomatosis TherapySemantic proximity Read

STAT1 Promotes PD-L1 Activation and Tumor Growth in LymphangioleiomyomatosisSemantic proximity Read

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)Semantic proximity Read

Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.Semantic proximity Read

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complexSemantic proximity Read

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis ComplexSemantic proximity Read

Extracellular Matrix-Induced Genes May Reduce Response to Rapamycin in LAMSemantic proximity Read

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complexSemantic proximity Read

Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.Semantic proximity Read

Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.Semantic proximity Read

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosisSemantic proximity Read